Fibrobiologics, Inc. (FBLG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fibrobiologics, Inc. on July 18, 2025, covering events occurring between June 20, 2025, and July 15, 2025. The filing details unregistered sales of equity securities pursuant to a Standby Equity Purchase Agreement (SEPA) entered into on December 20, 2024, with YA II PN, Ltd.
Key Financial Metrics and Transaction Details
The filing reports the conversion of convertible promissory notes into common stock. The filing text does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data for the period.
| Date | Note Converted | Principal Amount | Shares Issued | Conversion Price |
|---|---|---|---|---|
| June 20, 2025 | Second Note | $100,000 | 144,216 | $0.6934 |
| June 24, 2025 | Second Note | $200,000 | 295,377 | $0.6771 |
| June 26, 2025 | Third Note | $300,000 | 443,066 | $0.6771 |
| June 27, 2025 | Third Note | $500,000 | 738,443 | $0.6771 |
| July 15, 2025 | Third Note | $300,000 | 533,428 | $0.5624 |
Outstanding Debt Status:
- First Note: $5.0 million remaining principal balance.
- Second Note: Converted in full.
- Third Note: $3.9 million remaining principal balance.
Material Changes
The primary material change is the reduction of debt principal through equity conversion and the corresponding increase in outstanding common shares. The conversion price fluctuated during the period, dropping from $0.6934 to $0.5624 per share by July 15, 2025.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the securities were sold under Section 4(a)(2) of the Securities Act of 1933. The filing explicitly states it does not constitute an offer to sell securities.
Investor Verification Checklist
- Verify the total number of shares issued and the weighted average conversion price against the company's latest cap table.
- Confirm the remaining $8.9 million in convertible debt principal ($5.0m First Note + $3.9m Third Note) and its maturity terms.
- Review the impact of the declining conversion price (from $0.6934 to $0.5624) on existing shareholder dilution.
- Check subsequent filings for any further conversions of the First and Third Notes.